Chronic Leukemias

Chronic Leukemias

A collection of features and news articles published in ASH Clinical News related to chronic leukemias.

On location

Durable Efficacy With LOXO-305 in Heavily Pretreated CLL/SLL

LOXO-305, a highly selective noncovalent Bruton tyrosine kinase (BTK) inhibitor, was associated with promising response and efficacy rates in patients with heavily pretreated and...

The Future of Chronic Graft-Versus-Host Disease

An Update From the 3rd NIH Chronic GVHD Consensus Conference In this edition, Steven Pavletic, MD, and Kirk Schultz, MD, report on the progress and...
On location

Examining Immune Response in Patients with Hematologic Malignancy After COVID-19 Infection

Patients with a history of a hematologic malignancy who survive COVID-19 infection have similar immune responses against the virus following infection compared with people...

FDA Approves Ponatinib for Chronic-Phase CML

The U.S. Food and Drug Administration (FDA) has approved the supplemental new drug application for ponatinib to treat adults with chronic-phase chronic myeloid leukemia...
On location

Asciminib Beats Bosutinib in Treatment-Resistant Chronic Myeloid Leukemia

Asciminib, a first-in-class allosteric inhibitor that Specifically Targets ABL Myristoyl Pocket (STAMP), was more effective at achieving major molecular response (MMR) than bosutinib in...

Study Identifies Key Mutations That Promote Stem Cell Growth and Increase Leukemia Risk

In a report published in Nature, researchers linked three genetic loci to the increased proliferation of hematopoietic stem cells (HSCs), which may subsequently increase...

Anthony Mato: LOXO-305 Demonstrates Efficacy in Patients With CLL/SLL

Anthony Mato, MD, shares findings from a phase I/II trial evaluating LOXO-305 in patients with heavily pretreated chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL).

Andreas Hochhaus: Asciminib vs. Bosutinib in Chronic Myeloid Leukemia

Andreas Hochhaus, MD, discusses results from a phase I study suggesting asciminib may have superior efficacy to bosutinib in patients with heavily pretreated chronic...

Mogamulizumab Demonstrates Antitumor Activity in Adult T-Cell Leukemia/Lymphoma

Nearly two-thirds of patients with adult T-cell leukemia-lymphoma (ATLL) responded to treatment with mogamulizumab as a single agent or as part of a treatment...

Study Supports Earlier, More Frequent Use of Hospice in Older Patients With Hematologic Malignancies

Earlier and more frequent hospice use may be associated with a lower probability of inpatient death and a reduction in aggressive care at end...
Advertisement

Current Issue

July 2021 Bonus Mid-Year Edition, Volume 7 Issue 9

This issue features conversations with ASH Clinical Research Training Institute graduates, highlights from the virtual ASCO and EHA annual meetings, and more.

Block title